+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tumor-Infiltrating Lymphocyte Therapy Market - Global Forecast 2025-2030- Product Image
Tumor-Infiltrating Lymphocyte Therapy Market - Global Forecast 2025-2030- Product Image
Sale

Tumor-Infiltrating Lymphocyte Therapy Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081124
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Tumor infiltrating lymphocyte (TIL) therapy is redefining the global immuno-oncology landscape, helping healthcare stakeholders address treatment-resistant cancers by leveraging patient-derived immune cells. As advances in cell processing and regulatory clarity sweep the market, industry leaders are intensifying efforts to broaden patient access, streamline production, and drive clinical adoption.

Market Snapshot: Tumor Infiltrating Lymphocyte Therapy

The tumor infiltrating lymphocyte therapy market is demonstrating sustained growth, with demand surging across both established and emerging oncology centers. Key drivers include increasing recognition of TIL therapy’s ability to deliver durable responses in cancers unresponsive to standard therapies, a series of regulatory guidances supporting accelerated clinical development, and the maturation of adoptive immunotherapy platforms.

Scope & Segmentation

  • Indication: Breast cancer, lung cancer, melanoma
  • Cell Source: Autologous (patient-derived), allogeneic (donor-derived)
  • End User: Hospitals (infusion centers), research institutes, specialty clinics
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies
  • Manufacturing Model: Contract manufacturing organizations, in-house manufacturing
  • Regions: Americas (including United States, Canada, Brazil, Mexico, Argentina), Europe, Middle East, Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Companies Analyzed: Iovance Biotherapeutics, Inc.; Marker Therapeutics, Inc.; TILT Biotherapeutics; Instill Bio; Achilles Therapeutics

Emerging technological trends include automated bioreactors, high-throughput cell processing, next-generation sequencing for biomarker-driven patient selection, and integrated digital analytics for manufacturing and patient monitoring. Regional differences shape access and operational capacity, with advanced regulatory frameworks in the United States and Western Europe contrasted by market-building efforts in Asia-Pacific and parts of the Middle East and Africa.

Tumor Infiltrating Lymphocyte Therapy: Key Takeaways

  • Adoptive cell therapies using TILs are advancing rapidly, with new trial data confirming sustained responses in both solid tumors and traditionally refractory cancers.
  • Streamlined manufacturing enabled by closed-system bioreactors is accelerating turnaround times, supporting broader patient eligibility, and improving therapy scalability for both autologous and allogeneic approaches.
  • Collaborative regulatory environments are encouraging the use of adaptive trial designs, expediting pathways for TIL-based therapies, and supporting product standardization efforts across regions.
  • Strategic partnerships between developers, contract manufacturing organizations, and academic networks are facilitating knowledge transfer, driving innovation, and enabling tailored solutions for distinct geographic markets.
  • Digital solutions—including AI-powered analytics for process optimization and safety monitoring—are strengthening therapy predictability and responsiveness, supporting data-driven decision-making across development and commercialization.

Tariff Impact: Evolving Supply Chains and Strategic Response

Imposition of new United States tariffs in 2025 is affecting key inputs in the TIL therapy value chain, such as specialized cell culture media, recombinant cytokines, and ancillary single-use materials. Manufacturers are countering cost pressures by reshoring supply chains, engaging in tariff exemption efforts, and adopting dual-sourcing and forecasting strategies to sustain product flow and cost competitiveness.

Methodology & Data Sources

This analysis integrates primary interviews with industry executives, specialists, and investigators across core markets, supplemented by systematic reviews of peer-reviewed literature, clinical databases, regulatory filings, and validated operational metrics. Advanced modeling and scenario-based analysis underpin strategic forecasting and actionable recommendations.

Why This Report Matters

  • Provides clarity on evolving TIL therapy opportunities, helping decision-makers prioritize investments and alliances in a maturing market.
  • Equips senior leaders with essential perspectives to manage pricing, scale challenges, and regulatory expectations amid shifting policy and technological dynamics.
  • Enables targeted strategy formulation for market entry, regional expansion, or portfolio diversification.

Conclusion

Tumor infiltrating lymphocyte therapy is poised to reshape cancer care standards. Industry stakeholders who align with the latest developments, optimize operational models, and anticipate regulatory and supply chain trends will secure a leading role as this transformative field advances.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of high-throughput neoantigen profiling to optimize TIL targeting efficacy
5.2. Development of automated closed-system manufacturing to scale up TIL therapy production
5.3. Exploration of combination regimens combining TIL therapy with immune checkpoint inhibitors
5.4. Advancement of standardized potency assays to ensure batch-to-batch consistency in TIL products
5.5. Implementation of decentralized point-of-care manufacturing hubs to reduce TIL therapy delivery times
5.6. Emergence of off-the-shelf allogeneic TIL products to broaden patient access and reduce costs
5.7. Accumulating real-world evidence on long-term safety and efficacy outcomes of TIL therapy
5.8. Innovative cryopreservation techniques to maintain TIL viability during global distribution networks
5.9. Collaborative academic and industry partnerships accelerating TIL process optimization and clinical trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tumor-Infiltrating Lymphocyte Therapy Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.3. Lung Cancer
8.4. Melanoma
9. Tumor-Infiltrating Lymphocyte Therapy Market, by Cell Source
9.1. Introduction
9.2. Allogeneic
9.3. Autologous
10. Tumor-Infiltrating Lymphocyte Therapy Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Research Institutes
10.4. Specialty Clinics
11. Tumor-Infiltrating Lymphocyte Therapy Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Tumor-Infiltrating Lymphocyte Therapy Market, by Manufacturing Model
12.1. Introduction
12.2. Contract Manufacturing Organization
12.3. In-House Manufacturing
13. Americas Tumor-Infiltrating Lymphocyte Therapy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Tumor-Infiltrating Lymphocyte Therapy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Tumor-Infiltrating Lymphocyte Therapy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Iovance Biotherapeutics, Inc.
16.3.2. Marker Therapeutics, Inc.
16.3.3. TILT Biotherapeutics
16.3.4. Instill Bio
16.3.5. Achilles Therapeutics
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET: RESEARCHAI
FIGURE 26. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET: RESEARCHSTATISTICS
FIGURE 27. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET: RESEARCHCONTACTS
FIGURE 28. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 70. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 71. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 72. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 73. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 78. CANADA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 79. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 80. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 81. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 82. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 83. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 88. MEXICO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 131. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 134. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 135. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 140. GERMANY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 141. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 144. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 145. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 150. FRANCE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 161. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 164. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 165. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 170. ITALY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 171. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 172. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 173. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 174. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 175. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 180. SPAIN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 211. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 214. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 215. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 220. DENMARK TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 231. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 234. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 235. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 240. QATAR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 241. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 244. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 245. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 250. FINLAND TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 271. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 274. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 275. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 280. EGYPT TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 281. TURKEY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. TURKEY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. TURKEY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
TABLE 284. TURKEY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
TABLE 285. TURKEY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. TURKEY TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. TURKEY TUMOR-INFILTRATING LYMPHOCYTE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tumor-Infiltrating Lymphocyte Therapy market report include:
  • Iovance Biotherapeutics, Inc.
  • Marker Therapeutics, Inc.
  • TILT Biotherapeutics
  • Instill Bio
  • Achilles Therapeutics

Related Topics

Related Reports

Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity, Proprietary Technologies Platforms & Clinical Trials Insight 2030 - Product Image

Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity, Proprietary Technologies Platforms & Clinical Trials Insight 2030

  • Report
  • 180 Pages
  • Global
From
Tumor Infiltrating Lymphocytes Market Report 2025 - Product Image

Tumor Infiltrating Lymphocytes Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Cellular Immunotherapy Market Report 2025 - Product Image

Cellular Immunotherapy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
TIL Therapy - Pipeline Insight, 2025 - Product Image

TIL Therapy - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Cellular Immunotherapy Market - Global Forecast 2025-2032 - Product Image

Cellular Immunotherapy Market - Global Forecast 2025-2032

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.